17-hydroxyprogesterone ester containing oral compositions and related methods
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
1. A method of treating a pregnant female subject at risk of preterm birth, said method comprising administering to the female subject a tablet or capsule oral pharmaceutical composition comprising: a therapeutically effective amount of 17-hydroxyprogesterone caproate with a mean particle diameter size of 50 micron or less and a pharmaceutically acceptable carrier
wherein (a) said pharmaceutically acceptable carrier includes (i) a poloxamer, a polyethylene glycol sorbitan fatty acid ester, a sorbitan fatty acid ester, a polyethylene glycol glycerol fatty acid ester, sodium lauryl sulfate, sodium dioctyl sulfosuccinate, a lecithin, a bile salt or a combination thereof; or (ii) a lipophilic additive and (b) said pharmaceutical composition, when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5% (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., releases at least 20 wt % of the 17-hydroxyprogesterone caproate at 60 minutes.
2. The method of claim 1 , wherein the composition is formulated for pregnancy support.
3. The method of claim 1 , wherein the 17-hydroxyprogesterone caproate is micronized, sieved, milled, amorphous or nanosized.
4. The method of claim 1 , wherein the amount of the 17-hydroxyprogesterone caproate is from about 5% to about 80% w/w of the total composition.
5. The method of claim 1 , wherein the pharmaceutical composition further comprises polyvinylpyrrolidone, croscarmellose, microcrystalline cellulose, magnesium stearate, silicon dioxide, stearic acid, mannitol, a polyvinyl alcohol copolymer, a polyvinylpyrrolidone copolymer, a polyethylene glycol copolymer, a methacrylic acid copolymer, or a combination thereof.
6. The method of claim 1 , wherein the composition is in the form of a capsule and the capsule includes from about 30 mg to about 300 mg of 17-hydroxyprogesterone caproate.
7. The pharmaceutical composition of claim 1 , wherein the composition is a tablet and the tablet includes from about 20 mg to about 800 mg of 17-hydroxyprogesterone caproate.
8. The method of claim 1 wherein the pharmaceutically acceptable carrier further comprises a hydrophilic additive.
9. The method of claim 1 wherein the pharmaceutically acceptable carrier comprises a lipophilic additive.
10. The method of claim 1 wherein the pharmaceutically acceptable carrier comprises a lipophilic additive which is a lipophilic surfactant.
11. The method of claim 1 wherein the composition has an amount of 17-hydroxyprogesterone caproate equivalent to about 20 mg to 400 mg of 17-hydroxyprogesterone.
12. A method of treating a pregnant female subject at risk of preterm birth, said method comprising administering to the female subject a pharmaceutically acceptable tablet or capsule oral dosage form comprising: a therapeutically effective amount of 17-hydroxyprogesterone caproate and a pharmaceutically acceptable carrier, wherein said dosage form, when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5% w/v sodium lauryl sulfate at 50 RPM at 37° C., the oral dosage form releases at least 20 wt % of the 17-hydroxyprogesterone caproate at 60 minutes and wherein said pharmaceutically acceptable carrier includes (i) a poloxamer, a polyethylene glycol sorbitan fatty acid ester, a sorbitan fatty acid ester, a polyethylene glycol glycerol fatty acid ester, sodium lauryl sulfate, sodium dioctyl sulfosuccinate, a lecithin, a bile salt or a combination thereof or (ii) a lipophilic additive.
13. The method of claim 12 , wherein the oral dosage form is formulated for pregnancy support.
14. The method of claim 12 , wherein the 17-hydroxyprogesterone caproate is present in the oral dosage form in particulate form having a particulate mean diameter of about 50 μm or less.
15. The method of claim 12 , wherein the amount of the 17-hydroxyprogesterone caproate is from about 5% to 80% w/w of the total oral dosage form.
16. The method of claim 12 , wherein the 17-hydroxyprogesterone caproate is fully solubilized, partially solubilized or particulate.
17. The method of claim 13 , wherein the oral dosage form is a capsule and the capsule includes from about 10 mg to about 300 mg 17-hydroxyprogesterone caproate.
18. The pharmaceutical composition of claim 1 , wherein the oral dosage form is a tablet and the tablet includes from about 20 mg to about 800 mg of 17-hydroxyprogesterone caproate.
19. A method of treating a pregnant female subject at risk of preterm birth, said method comprising administering to the female subject a tablet or capsule pharmaceutically acceptable oral dosage form comprising: a therapeutically effective amount of 17-hydroxyprogesterone caproate and a pharmaceutically acceptable carrier, wherein said dosage form, when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5% (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., the oral dosage form releases at least 20 wt % of the 17-hydroxyprogesterone caproate at 60 minutes and wherein said pharmaceutically acceptable carrier includes (a) a hydrophilic surfactant which is a poloxamer, a polyethylene glycol sorbitan fatty acid ester, a sorbitan fatty acid ester, a polyethylene glycol glycerol fatty acid ester, sodium lauryl sulfate, sodium dioctyl sulfosuccinate, a lecithin, a bile salt or a combination thereof and (b) further comprises polyvinylpyrrolidone, croscarmellose, microcrystalline cellulose, magnesium stearate, silicon dioxide, stearic acid, mannitol, a polyvinyl alcohol copolymer, a polyvinylpyrrolidone copolymer, a polyethylene glycol copolymer, a methacrylic acid copolymer, or a combination thereof.
20. The method of claim 19 , wherein the 17 hydroxyprogesterone caproate is present in the oral dosage form in particulate form having a particulate mean diameter of about 50 μm or less.